id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2007-D-0369-0399,FDA,FDA-2007-D-0369,"Product-Specific Bioequivalence Recommendations; Draft and Revised
Draft Guidances for Industry; Availability",Notice,Notice of Availability,2016-12-23T05:00:00Z,2016,12,2016-12-23T05:00:00Z,2017-02-22T04:59:59Z,2017-03-08T02:01:43Z,2016-30984,0,0,09000064824338b3
FDA-2007-D-0369-0397,FDA,FDA-2007-D-0369,"Bioequivalence Recommendations for Cyclobenzaprine Hydrochloride;
Revised Draft Guidance for Industry; Availability",Notice,Notice of Availability,2016-11-25T05:00:00Z,2016,11,2016-11-25T05:00:00Z,2017-01-25T04:59:59Z,2016-11-25T14:45:56Z,2016-28334,0,0,09000064823beea5
FDA-2007-D-0369-0392,FDA,FDA-2007-D-0369,"Product-Specific Bioequivalence Recommendations; Draft and Revised
Draft Guidances for Industry; Availability",Notice,Notice of Availability,2016-10-05T04:00:00Z,2016,10,2016-10-05T04:00:00Z,2016-12-06T04:59:59Z,2016-12-06T14:04:42Z,2016-24050,0,0,090000648229a04c
FDA-2007-D-0369-0390,FDA,FDA-2007-D-0369,"Bioequivalence Recommendations for Risperidone; Draft Guidance for
Industry; Availability",Notice,Guidance,2016-08-30T04:00:00Z,2016,8,2016-08-30T04:00:00Z,2016-11-01T03:59:59Z,2016-11-01T01:01:58Z,2016-20778,0,0,09000064821ae192
FDA-2007-D-0369-0389,FDA,FDA-2007-D-0369,"Bioequivalence Recommendations for Fidaxomicin; Draft Guidance for
Industry; Availability",Notice,Notice of Availability,2016-08-24T04:00:00Z,2016,8,2016-08-24T04:00:00Z,,2016-08-24T14:28:13Z,2016-20146,0,0,090000648219797c
FDA-2007-D-0369-0387,FDA,FDA-2007-D-0369,Bioequivalence Recommendations for Paliperidone Palmitate; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2016-07-01T04:00:00Z,2016,7,2016-07-01T04:00:00Z,2016-09-07T03:59:59Z,2024-11-12T06:09:25Z,2016-15663,1,0,090000648208058a
FDA-2007-D-0369-0386,FDA,FDA-2007-D-0369,Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability,Notice,Notice of Availability,2016-06-17T04:00:00Z,2016,6,2016-06-17T04:00:00Z,2016-08-17T03:59:59Z,2016-06-17T14:20:19Z,2016-14351,0,0,090000648204af5a
FDA-2007-D-0369-0379,FDA,FDA-2007-D-0369,"Product-Specific Bioequivalence Recommendations; Draft and Revised
Draft Guidances for Industry; Availability",Notice,Notice of Availability,2016-04-15T04:00:00Z,2016,4,2016-04-15T04:00:00Z,,2024-11-07T23:45:39Z,2016-08682,1,0,0900006481f6c060
FDA-2007-D-0369-0377,FDA,FDA-2007-D-0369,"Supplement from Janssen Research & Development, LLC",Other,Supplement (SUP),2016-03-02T05:00:00Z,2016,3,2016-03-02T05:00:00Z,,2016-03-02T17:01:54Z,,0,0,0900006481e88283
FDA-2007-D-0369-0376,FDA,FDA-2007-D-0369,Supplemental Comment from GlaxoSmithKline,Supporting & Related Material,Background Material,2016-02-19T05:00:00Z,2016,2,,,2016-02-19T19:50:20Z,,0,0,0900006481e7873d
FDA-2007-D-0369-0375,FDA,FDA-2007-D-0369,"Bioequivalence Recommendations for Cyclosporine; Draft Guidance for
Industry; Availability",Notice,Notice of Availability,2016-02-16T05:00:00Z,2016,2,2016-02-16T05:00:00Z,2016-04-19T03:59:59Z,2016-04-19T03:00:38Z,2016-02975,0,0,0900006481e6e395
FDA-2007-D-0369-0372,FDA,FDA-2007-D-0369,"Product-Specific Bioequivalence Recommendations; Draft and Revised
Draft Guidances for Industry; Availability",Notice,Notice of Availability,2016-01-28T05:00:00Z,2016,1,2016-01-28T05:00:00Z,,2024-11-12T05:55:26Z,2016-01682,1,0,0900006481e35c6a
FDA-2007-D-0369-0373,FDA,FDA-2007-D-0369,"Bioequivalence Recommendations for Lamotrigine; Draft Guidance for
Industry; Availability",Notice,Notice of Availability,2016-01-28T05:00:00Z,2016,1,2016-01-28T05:00:00Z,2016-03-29T03:59:59Z,2016-01-28T17:08:30Z,2016-01683,0,0,0900006481e35ca7